UG Healthcare - Phillip Securities 2021-02-08: Another Blockbuster Quarter

UG HEALTHCARE CORPORATIONLTD (SGX:8K7)

UG Healthcare - Another Blockbuster Quarter

UG Healthcare (SGX:8K7)'s 1H21 PATMI jumped 64x y-o-y to S$54.9mn as revenue tripled to S$159mn, beating our forecast by 22%. Gross margins leapt from 18% to 62% y-o-y as selling prices rose more than 1.5x to S$117 per 1,000 pieces. UG Healthcare sells both nitrile and latex gloves.
Maintain BUY. We raise our UG Healthcare FY21e PATMI forecast by 28% to S$107.8mn to account for higher glove selling prices and margins.
Our target price for UG Healthcare remains pegged at a 30% P/E discount to the Big 4 glove makers’ FY22e valuations. As rubber glove valuations have compressed to around 10x P/E, our target P/E for FY22e drops from 14x to 7x. This lowers our target price from S$1.35 to S$1.03.

UG Healthcare's 1H21 revenue tripled y-o-y to S$159mn with an estimated 20% growth in volume and 1.5x jump in prices. Sales to China spiked 457% y-o-y as customers stocked up ahead of winter and the festive season.

UG Healthcare's 1H21 gross margin was 62%, triple that of 1H20 as glove prices skyrocketed. q-o-q, margins expanded from 60.6% in 1Q21 to 63.6% in 2Q21.

UG Healthcare's cash from operations rose to S$45.9mn. The company now has net cash of S$32.5mn, a major reversal from net debt of S$37mn a year ago. UG Healthcare announced a special dividend of S$0.00105 and a total payout of S$0.645mn.

There have been shipment delays. As a result, inventories almost doubled in the past six months to S$57mn. Inventories were predominantly finished goods on transit to Europe. Container constraints are expected to ease only after February. Shipping rates to Europe have catapulted almost 5-fold to around US$10,000 per container. Even then, shipping rates only account for around 2% of UG Healthcare’s selling prices.

Earnings are still expected to grow q-o-q as prices continue to climb in 2021. We also see other growth drivers for UG Healthcare even if glove prices taper off.
- Firstly, production capacity will expand by 35% y-o-y to 4.6bn pieces in FY22e.
- Secondly, exposure to emerging markets and low penetration rates could provide sources of growth.

ASPs for nitrile and latex gloves are around US$130-140 and US$90-95 per 1,000 pieces respectively. Demand is still outstripping supply. Latex prices can climb faster in 2021, driven by emerging markets.
Securing sufficient foreign workers will be a priority if UG Healthcare expands further. Every week, workers have to undergo COVID-19 antigen tests.
UG Healthcare’s pricing policy is not to “max out” prices to customers. It emphasises supporting long-term dedicated customers during this period of tight supply.
UG Healthcare’s priority is to conserve cash for expansion that requires new land and downstream capacity such as warehouses.
Nitrile raw material prices are starting to stabilise.
An additional 500mn of capacity to 3.4bn pieces will come on stream in April 2021. A new 1.2bn capacity plant is under construction with commissioning expected in 1Q22 (Jul-Sep 2022). UG Healthcare is studying plans for expanding above 4.6bn.

See UG Healthcare Share Price; UG Healthcare Target Price; UG Healthcare Analyst Reports; UG Healthcare Dividend History; UG Healthcare Announcements; UG Healthcare Latest News.
We continue to value UG Healthcare at a 30% discount to the Big 4 glove makers (Top Glove (SGX:BVA), Hartalega, Supermax, Kossan Rubber). Historically, UG Healthcare’s discount was around 40%. As industry valuations have corrected to around 10x P/E, our target P/E for FY22e drops from 14x to 7x. This lowers our target price from S$1.35 to S$1.03. See comparison of UG Healthcare with peers including the Big 4 glove makers as well as Riverstone (SGX:AP4) in PDF report attached below.
We raise our UG Healthcare FY21e PATMI forecast by 28% to S$107.8mn to account for the continuous rise in its ASPs and margins. Our FY22e PATMI assumes a 24% y-o-y contraction in ASPs to around S$80 per 1,000 gloves. We also assume a 15% increase in production costs in FY22e.

See also recent SGX market update: SGX Listed Medical Suppliers Continued to Trade Actively in January 2021.

Paul Chew Phillip Securities Research | https://www.stocksbnb.com/ 2021-02-08

SGX Stock Analyst Report BUY MAINTAIN BUY 1.03 DOWN 1.350